Myofascial Pain Syndromes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major myofascial pain syndromes markets are expected to exhibit a CAGR of 2.69% during 2024-2034.
The myofascial pain syndromes market has been comprehensively analyzed in IMARC's new report titled "Myofascial Pain Syndromes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myofascial pain syndromes refer to a group of conditions characterized by chronic pain in the musculoskeletal system, specifically in the muscles and their surrounding connective tissues called fascia. The pain is typically localized to certain trigger points, which are sensitive areas within the muscle. The symptoms of these syndromes may vary from person to person but commonly include persistent, deep, and aching pain in the affected regions, restricted range of motion, a sensation of weakness, poor sleep quality, fatigue, decreased energy levels, etc. Individuals suffering from the condition may also experience emotional distress, such as feelings of frustration, anxiety, depression, etc. The diagnosis of myofascial pain syndromes typically involves a thorough combination of medical history, physical examination, and laboratory tests. Electromyography is also recommended to measure the electrical activity of muscles and detect any abnormalities associated with the disease. The healthcare provider may further perform various diagnostic procedures, like ultrasound or magnetic resonance imaging, to visualize the muscle tissue, identify trigger points, and confirm the presence of tender nodules in patients.
The increasing cases of muscle imbalances due to several factors, such as muscle weakness, tightness, altered movement patterns, etc., leading to the development of trigger points, are primarily driving the myofascial pain syndromes market. In addition to this, the inflating application of over-the-counter pain relievers, including ibuprofen and acetaminophen, which can manage pain and improve treatment outcomes, is also creating a positive outlook for the market. Moreover, the widespread adoption of transcutaneous electrical nerve stimulation (TENS) techniques, since they use a small device that transmits electrical currents to the muscles, helping to minimize disease symptoms and muscle tension, is further bolstering the market growth. Apart from this, the rising demand for stress management procedures, owing to their numerous benefits, like promoting better sleep quality, enhancing pain coping mechanisms, lowering inflammation, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of trigger point injections, which involve injecting a mixture of anesthetics and steroids into sensitive areas to improve flexibility and functional abilities, is expected to drive the myofascial pain syndromes market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the myofascial pain syndromes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myofascial pain syndromes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myofascial pain syndromes market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myofascial pain syndromes market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myofascial pain syndromes market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myofascial pain syndromes marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the myofascial pain syndromes market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myofascial pain syndromes market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myofascial pain syndromes market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of myofascial pain syndromes across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of myofascial pain syndromes by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of myofascial pain syndromes by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with myofascial pain syndromes across the seven major markets?
What is the size of the myofascial pain syndromes patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myofascial pain syndromes?
What will be the growth rate of patients across the seven major markets?
Myofascial Pain Syndromes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myofascial pain syndromes drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myofascial pain syndromes market?
What are the key regulatory events related to the myofascial pain syndromes market?
What is the structure of clinical trial landscape by status related to the myofascial pain syndromes market?
What is the structure of clinical trial landscape by phase related to the myofascial pain syndromes market?
What is the structure of clinical trial landscape by route of administration related to the myofascial pain syndromes market?
The myofascial pain syndromes market has been comprehensively analyzed in IMARC's new report titled "Myofascial Pain Syndromes Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myofascial pain syndromes refer to a group of conditions characterized by chronic pain in the musculoskeletal system, specifically in the muscles and their surrounding connective tissues called fascia. The pain is typically localized to certain trigger points, which are sensitive areas within the muscle. The symptoms of these syndromes may vary from person to person but commonly include persistent, deep, and aching pain in the affected regions, restricted range of motion, a sensation of weakness, poor sleep quality, fatigue, decreased energy levels, etc. Individuals suffering from the condition may also experience emotional distress, such as feelings of frustration, anxiety, depression, etc. The diagnosis of myofascial pain syndromes typically involves a thorough combination of medical history, physical examination, and laboratory tests. Electromyography is also recommended to measure the electrical activity of muscles and detect any abnormalities associated with the disease. The healthcare provider may further perform various diagnostic procedures, like ultrasound or magnetic resonance imaging, to visualize the muscle tissue, identify trigger points, and confirm the presence of tender nodules in patients.
The increasing cases of muscle imbalances due to several factors, such as muscle weakness, tightness, altered movement patterns, etc., leading to the development of trigger points, are primarily driving the myofascial pain syndromes market. In addition to this, the inflating application of over-the-counter pain relievers, including ibuprofen and acetaminophen, which can manage pain and improve treatment outcomes, is also creating a positive outlook for the market. Moreover, the widespread adoption of transcutaneous electrical nerve stimulation (TENS) techniques, since they use a small device that transmits electrical currents to the muscles, helping to minimize disease symptoms and muscle tension, is further bolstering the market growth. Apart from this, the rising demand for stress management procedures, owing to their numerous benefits, like promoting better sleep quality, enhancing pain coping mechanisms, lowering inflammation, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of trigger point injections, which involve injecting a mixture of anesthetics and steroids into sensitive areas to improve flexibility and functional abilities, is expected to drive the myofascial pain syndromes market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the myofascial pain syndromes market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myofascial pain syndromes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myofascial pain syndromes market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myofascial pain syndromes market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myofascial pain syndromes market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myofascial pain syndromes marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the myofascial pain syndromes market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myofascial pain syndromes market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myofascial pain syndromes market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of myofascial pain syndromes across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of myofascial pain syndromes by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of myofascial pain syndromes by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with myofascial pain syndromes across the seven major markets?
What is the size of the myofascial pain syndromes patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myofascial pain syndromes?
What will be the growth rate of patients across the seven major markets?
Myofascial Pain Syndromes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myofascial pain syndromes drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myofascial pain syndromes market?
What are the key regulatory events related to the myofascial pain syndromes market?
What is the structure of clinical trial landscape by status related to the myofascial pain syndromes market?
What is the structure of clinical trial landscape by phase related to the myofascial pain syndromes market?
What is the structure of clinical trial landscape by route of administration related to the myofascial pain syndromes market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYOFASCIAL PAIN SYNDROMES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYOFASCIAL PAIN SYNDROMES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYOFASCIAL PAIN SYNDROMES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 MYOFASCIAL PAIN SYNDROMES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYOFASCIAL PAIN SYNDROMES - UNMET NEEDS
10 MYOFASCIAL PAIN SYNDROMES - KEY ENDPOINTS OF TREATMENT
11 MYOFASCIAL PAIN SYNDROMES - MARKETED PRODUCTS
11.1 List of Myofascial Pain Syndromes Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MYOFASCIAL PAIN SYNDROMES - PIPELINE DRUGS
12.1 List of Myofascial Pain Syndromes Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MYOFASCIAL PAIN SYNDROMES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYOFASCIAL PAIN SYNDROMES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYOFASCIAL PAIN SYNDROMES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myofascial Pain Syndromes - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myofascial Pain Syndromes - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myofascial Pain Syndromes - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myofascial Pain Syndromes - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myofascial Pain Syndromes - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myofascial Pain Syndromes - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myofascial Pain Syndromes - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myofascial Pain Syndromes - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myofascial Pain Syndromes - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myofascial Pain Syndromes - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myofascial Pain Syndromes - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myofascial Pain Syndromes - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myofascial Pain Syndromes - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myofascial Pain Syndromes - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myofascial Pain Syndromes - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myofascial Pain Syndromes - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
16 MYOFASCIAL PAIN SYNDROMES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYOFASCIAL PAIN SYNDROMES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYOFASCIAL PAIN SYNDROMES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYOFASCIAL PAIN SYNDROMES - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYOFASCIAL PAIN SYNDROMES - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYOFASCIAL PAIN SYNDROMES - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 MYOFASCIAL PAIN SYNDROMES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYOFASCIAL PAIN SYNDROMES - UNMET NEEDS
10 MYOFASCIAL PAIN SYNDROMES - KEY ENDPOINTS OF TREATMENT
11 MYOFASCIAL PAIN SYNDROMES - MARKETED PRODUCTS
11.1 List of Myofascial Pain Syndromes Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MYOFASCIAL PAIN SYNDROMES - PIPELINE DRUGS
12.1 List of Myofascial Pain Syndromes Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. MYOFASCIAL PAIN SYNDROMES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYOFASCIAL PAIN SYNDROMES – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYOFASCIAL PAIN SYNDROMES - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myofascial Pain Syndromes - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myofascial Pain Syndromes - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myofascial Pain Syndromes - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myofascial Pain Syndromes - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myofascial Pain Syndromes - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myofascial Pain Syndromes - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myofascial Pain Syndromes - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myofascial Pain Syndromes - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myofascial Pain Syndromes - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myofascial Pain Syndromes - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myofascial Pain Syndromes - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myofascial Pain Syndromes - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myofascial Pain Syndromes - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myofascial Pain Syndromes - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myofascial Pain Syndromes - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myofascial Pain Syndromes - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myofascial Pain Syndromes - Access and Reimbursement Overview
16 MYOFASCIAL PAIN SYNDROMES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYOFASCIAL PAIN SYNDROMES MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYOFASCIAL PAIN SYNDROMES MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
